# US 2020/0390816 A1 · Methods for activation and expansion of natural killer cells and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390816 A1
- Document ID: US20200390816A1
- Status: Published application
- Kind: A1
- Application number: 16/970,937
- Filed: 2019-02-21
- Published: 2020-12-17
- Earliest claimed: 2018-02-21
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, The University of Texas System
- Inventors: Lucilla Nassif Kerbauy; Elizabeth Shpall; Katy Rezvani
- Web page: https://patentgrep.com/patent/US20200390816A1

## CPC

- C07K 14/5434: {IL-12}
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/35: Cytokines
- A61K 40/4211: {CD19 or B4}
- A61K 40/4217: {Receptors for interleukins [IL]}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/47: from mammals
- C07K 14/5443: {IL-15}
- C07K 14/55: IL-2
- C07K 14/70592: {CD52}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 2319/03: containing a transmembrane segment
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2312: Interleukin-12 (IL-12)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/2318: Interleukin-18 (IL-18)
- C12N 2501/2321: Interleukin-21 (IL-21)
- C12N 2501/25: Tumour necrosing factors [TNF]
- C12N 2501/515: CD3, T-cell receptor complex
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are methods for pre-activating and expanding an isolated population of NK cells. Further provided herein are methods for the treatment of cancer by administering the pre-activated and expanded NK cells.

## Claims

### Claim 1

An in vitro method for expanding natural killer (NK) cells comprising:
(a) obtaining a population of NK cells;
(b) pre-activating the population of NK cells in a pre-activation culture comprising an effective concentration of IL-12, IL-15, and IL-18 to obtain pre-activated NK cells; and
(c) expanding the pre-activated NK cells in an expansion culture comprising artificial antigen presenting cells (aAPCs) expressing CD137 ligand, thereby producing expanded NK cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the population of NK cells is obtained from cord blood (CB), peripheral blood (PB), stem cells, or bone marrow.

### Claim 3 (depends on 2)

The method of claim 2, wherein the stem cells are induced pluripotent stem cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the population of NK cells is obtained from CB.

### Claim 5 (depends on 4)

The method of claim 4, wherein the CB is pooled from 2 or more individual cord blood units.

### Claim 6 (depends on 4)

The method of claim 4, wherein the CB is pooled from 3, 4, 5, 6, 7, or 8 individual cord blood units.

### Claim 7 (depends on 1)

The method of claim 1, wherein the population of NK cells are CB mononuclear cells (CBMCs).

### Claim 8 (depends on 1)

The method of claim 1, wherein the population of NK cells are further defined as CD56+ NK cells.

### Claim 9 (depends on 1)

The method of claim 1, wherein the aAPCs further express a membrane-bound cytokine.

### Claim 10 (depends on 9)

The method of claim 9, wherein the membrane-bound cytokine is membrane-bound IL-21 (mIL-21) or membrane-bound IL-15 (mIL-15).

### Claim 11 (depends on 9)

The method of claim 9, wherein the membrane-bound cytokine is mIL-21.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the aAPCs have essentially no expression of endogenous HLA class I, II, or CD1d molecules.

### Claim 13 (depends on 1)

The method of claim 1, wherein the aAPCs express ICAM-1 (CD54) and LFA-3 (CD58).

### Claim 14 (depends on 1)

The method of claim 1, wherein the aAPCs are further defined as leukemia cell-derived aAPCs.

### Claim 15 (depends on 14)

The method of claim 14, wherein the leukemia-cell derived aAPCs are K562 cells engineered to express CD137 ligand and/or mIL-21.

### Claim 16 (depends on 15)

The method of claim 15, wherein the K562 cells are engineered to express CD137 ligand and mIL-21.

### Claim 17 (depends on 15)

The method of claim 15, wherein the aAPCs have been engineered by retroviral transduction.

### Claim 18 (depends on 1)

The method of claim 1, wherein the aAPCs are irradiated.

### Claim 19 (depends on 1)

The method of claim 1, wherein the pre-activating step is for 10-20 hours.

### Claim 20 (depends on 1)

The method of claim 1, wherein the pre-activating step is for 14-18 hours.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the pre-activating step is for 16 hours.

### Claim 22 (depends on 1)

The method of claim 1, wherein the pre-activation culture comprises IL-18 and/or IL-15 at a concentration of 10-100 ng/mL.

### Claim 23 (depends on 1)

The method of claim 1, wherein the pre-activation culture comprises IL-18 and/or IL-15 at a concentration of 40-60 ng/mL.

### Claim 24 (depends on 1)

The method of claim 1, wherein the pre-activation culture comprises IL-18 and/or II-15 at a concentration of 50 ng/mL.

### Claim 25 (depends on 1)

The method of claim 1, wherein the pre-activation culture comprises IL-12 at a concentration of 0.1-150 ng/mL.

### Claim 26 (depends on 1)

The method of claim 1, wherein the pre-activation culture comprises IL-12 at a concentration of 1-20 ng/mL.

### Claim 27 (depends on 1)

The method of claim 1, wherein the pre-activation culture comprises IL-12 at a concentration of 10 ng/mL.

### Claim 28 (depends on 1)

The method of claim 1, further comprising washing the pre-activated NK cells prior to expanding.

### Claim 29 (depends on 28)

The method of claim 28, wherein washing is performed multiple times.

### Claim 30 (depends on 1)

The method of claim 1, wherein expanding is for 5-20 days.

### Claim 31 (depends on 1)

The method of claim 1, wherein the expanding is for 12-16 days.

### Claim 32 (depends on 1)

The method of claim 1, wherein the expanding is for 14 days.

### Claim 33 (depends on 1)

The method of claim 1, wherein the pre-activated NK cells and aAPCs are present in the expansion culture at a ratio of 3:1 to 1:3.

### Claim 34 (depends on 1)

The method of claim 1, wherein the pre-activated NK cells and aAPCs are present in the expansion culture at a ratio 1:2.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-34, wherein the expansion culture further comprises IL-2.

### Claim 36 (depends on 35)

The method of claim 35, wherein the IL-2 is present at a concentration of 10-500 U/mL.

### Claim 37 (depends on 35)

The method of claim 35, wherein the IL-2 is present at a concentration of 100-300 U/mL.

### Claim 38 (depends on 35)

The method of claim 35, wherein the IL-2 is present at a concentration of 200 U/mL.

### Claim 39 (depends on 35)

The method of claim 35, wherein the IL-12, IL-18, IL-15, and/or IL-2 is recombinant human IL-2.

### Claim 40 (depends on 35)

The method of claim 35, wherein the IL-2 is replenished in the expansion culture every 2-3 days.

### Claim 41 (depends on 1)

The method of claim 1, wherein the aAPCs are added to the expansion culture at least a second time.

### Claim 42 (depends on 1)

The method of claim 1, wherein the method is performed in serum-free media.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 1-42, wherein the NK cells are engineered to express a chimeric antigen receptor (CAR).

### Claim 44 (depends on 43)

The method of claim 43, wherein the CAR comprises a humanized antigen-binding domain.

### Claim 45 (depends on 43)

The method of claim 43, wherein the CAR comprises a CD19, CD123, mesothelin, CD5, CD47, CLL-1, CD33, CD99, U5snRNP200, CD200, CS1, BAFF-R, ROR-1, or BCMA antigen-binding domain.

### Claim 46 (depends on 43)

The method of claim 43, wherein the CAR comprises a CD19 or CD123 antigen-binding domain.

### Claim 47 (depends on 43)

The method of claim 43, wherein the CAR comprises IL-15.

### Claim 48 (depends on 43)

The method of claim 43, wherein the CAR comprises a suicide gene.

### Claim 49 (depends on 43)

The method of claim 43, wherein the suicide gene is CD20, CD52, EGFRv3, or inducible caspase 9.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

A population of expanded NK cells produced according to the methods of any one of claims 1-49.

### Claim 51 (depends on 50)

A pharmaceutical composition comprising the population of expanded NK cells of claim 50 and a pharmaceutically acceptable carrier.

### Claim 52 (depends on 50)

A composition comprising an effective amount of the expanded NK cells of claim 50 for use in the treatment of a disease or disorder in a subject.

### Claim 53 (depends on 52)

The composition of claim 52, wherein the disease or disorder is cancer, inflammation, graft versus host disease, transplant rejection, an autoimmune disorder, an immunodeficiency disease, a B cell malignancy, or an infection.

### Claim 54 (depends on 53)

The composition of claim 53, wherein the cancer is a leukemia.

### Claim 55 (depends on 54)

The composition of claim 54, wherein the leukemia is an acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), or a chronic myelogenous leukemia (CIVIL).

### Claim 56 (depends on 52)

The composition of claim 52, wherein the disorder is graft versus host disease (GVHD).

### Claim 57 (depends on 52)

The composition of claim 52, wherein the disorder is multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, type I diabetes, systemic lupus erythrematosus, contact hypersensitivity, asthma or Sjogren's syndrome.

### Claim 58 (depends on 50)

A method of treating a disease or disorder in a subject comprising administering a therapeutically effective amount of the expanded NK cells of claim 50 to the subject.

### Claim 59 (depends on 58)

The method of claim 58, wherein the disease or disorder is cancer, inflammation, graft versus host disease, transplant rejection, an autoimmune disorder, an immunodeficiency disease, a B cell malignancy, or an infection.

### Claim 60 (depends on 58)

The method of claim 58, wherein the cancer is a leukemia.

### Claim 61 (depends on 60)

The method of claim 60, wherein the leukemia is an acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML), or a chronic myelogenous leukemia (CIVIL).

### Claim 62 (depends on 58)

The method of claim 58, wherein the NK cells are allogeneic.

### Claim 63 (depends on 58)

The method of claim 58, wherein the NK cells are autologous.

### Claim 64 (depends on 58)

The method of claim 58, wherein the disorder is graft versus host disease (GVHD).

### Claim 65 (depends on 58)

The method of claim 58, wherein the disorder is multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, type I diabetes, systemic lupus erythrematosus, contact hypersensitivity, asthma or Sjogren's syndrome.

### Claim 66 (depends on 58)

The method of claim 58, wherein the subject is a human.

### Claim 67 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 58-66, further comprising administering at least a second therapeutic agent.

### Claim 68 (depends on 67)

The method of claim 67, wherein the at least a second therapeutic agent is a therapeutically effective amount of an anti-cancer agent, immunomodulatory agent, or an immunosuppressive agent.

### Claim 69 (depends on 68)

The method of claim 68, wherein the anti-cancer agent is chemotherapy, radiotherapy, gene therapy, surgery, hormonal therapy, anti-angiogenic therapy or immunotherapy.

### Claim 70 (depends on 68)

The method of claim 68, wherein the immunosuppressive agent is a calcineurin inhibitor, an mTOR inhibitor, an antibody, a chemotherapeutic agent irradiation, a chemokine, an interleukins or an inhibitor of a chemokine or an interleukin.

### Claim 71 (depends on 67)

The method of claim 67, wherein NK cells and/or the at least a second therapeutic agent are administered intravenously, intraperitoneally, intratracheally, intratumorally, intramuscularly, endoscopically, intralesionally, percutaneously, subcutaneously, regionally, or by direct injection or perfusion.

### Claim 72 (depends on 67)

The method of claim 67, wherein the second therapeutic agent is an antibody.

### Claim 73 (depends on 72)

The method of claim 72, wherein the antibody if a monoclonal, bispecific, or trispecific antibody.

### Claim 74 (depends on 72)

The method of claim 72, wherein the antibody is a monoclonal antibody.

### Claim 75 (depends on 72)

The method of claim 72, wherein the antibody is rituximab.
